Pharmacokinetics of Recombinant Interferon-α 2 Following Intralesional Administration in Malignant Glioma Patients

Abstract

Pharmacokinetics of recombinant interferon-α₂ (rIFN-α₂) following intralesional administration into patients with malignant gliomas was investigated. A dose of 5 × 10⁶ IU of rIFN-α₂ was injected locally postoperatively for 2 weeks each day, and the same dose was then given once a week for 10 additional weeks. During the daily and weekly administration, the IFN was consistently present in the fluid of the postsurgical cavity. Not until 5 weeks after the end of the IFN administration was the IFN undetectable. The decay of IFN injected was minimal.